alexa Biosimilar Of Protein Therapeutics
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars
October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Alok Bandyopadhyay
Accepted Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.015
Abstract
Protein therapeutics, including monoclonal antibodies and cytokines, have become mainstream treatments in a number of clinical settings starting from pain control, cardiovascular to oncology. All these biological drugs are expensive.In order to develop inexpensive patients? treatments, biosimilar of these branded drugs are required. Formulation, manufacturing and various other chemistry, manufacturing and controls (CMC) information of the branded drugs are different from biosimilar. Manufacturing of the biological drugs are long multistep processes and complex. During formulation and manufacturing processes the drug product may be associated with product-related, process-related, and/or host-related impurities through degradation, deamidation, misfolding, or aggregation. When it is administered within the body, these impurities may also produce antibodies in addition to the antibody of drug substances. Moreover, protein aggregation in particular has long been associated with increased immunogenicity. Repeated administration of drug product may cause a break in immune tolerance that can adversely affect pharmacokinetics and clinical response. In addition, neutralizing antibodies that cross reacts with nonredundant proteins may be a cause of autoimmune reaction. Well designed formulation coupled with good protein purification scheme may sometimes reduce the formation of product related impurities and increase the stability of drug product. One of the best remedy will be to purify the drug product to homogeneity or near homogeneity retaining its stability and functional activity, which may not trigger immunogenicity or other clinical issues due to negligible content of impurities. At the same time more discussions with Agency are required for quicker review and approval like FDA?s ?breakthrough therapy pathway? for the drug used in life threatening more serious illness. Near homogeneous protein and frequent discussion with agency may open up the easier regulatory pathway for biosimilar approval. Interchangeability and price reduction issues may be solved at that time.
Biography
Alok Bandyopadhyay, PhD, RAC is a consultant with more than 15 years of pharmaceutical experience. He held positions at several pharmaceutical companies and has published more than 75 articles and abstracts.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords